Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2018

Global Markets Direct’s, ‘Attention Deficit Hyperactivity Disorder (ADHD) - Pipeline Review, H2 2018’, provides an overview of the Attention Deficit Hyperactivity Disorder (ADHD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Attention Deficit Hyperactivity Disorder (ADHD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Attention Deficit Hyperactivity Disorder (ADHD)

- The report reviews pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD) by companies and universities/research institutes based on information derived from company and industry-specific sources

- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

- The report reviews key players involved Attention Deficit Hyperactivity Disorder (ADHD) therapeutics and enlists all their major and minor projects

- The report assesses Attention Deficit Hyperactivity Disorder (ADHD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

- The report summarizes all the dormant and discontinued pipeline projects

- The report reviews latest news related to pipeline therapeutics for Attention Deficit Hyperactivity Disorder (ADHD)

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Attention Deficit Hyperactivity Disorder (ADHD)

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Attention Deficit Hyperactivity Disorder (ADHD) pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

4P-Pharma SAS

Aevi Genomic Medicine Inc

Amarantus Bioscience Holdings Inc

APeT Holding BV

Arcturus Therapeutics Ltd

BCWorld Pharm Co Ltd

BioHealthonomics Inc

Cingulate Therapeutics LLC ...

4P-Pharma SAS

Aevi Genomic Medicine Inc

Amarantus Bioscience Holdings Inc

APeT Holding BV

Arcturus Therapeutics Ltd

BCWorld Pharm Co Ltd

BioHealthonomics Inc

Cingulate Therapeutics LLC

Collegium Pharmaceutical Inc

Curemark LLC

DURECT Corp

Heptares Therapeutics Ltd

Highland Therapeutics Inc

IRLAB Therapeutics AB

KemPharm Inc

leon-nanodrugs GmbH

Merck & Co Inc

Novartis AG

Noven Pharmaceuticals Inc

Otsuka Holdings Co Ltd

Otsuka Pharmaceutical Co Ltd

P2D Inc

RespireRx Pharmaceuticals Inc

Reviva Pharmaceuticals Inc

Shionogi & Co Ltd

Shire Plc

SK Biopharmaceuticals Co Ltd

Sunovion Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Taisho Pharmaceutical Holdings Co Ltd

Tris Pharma Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Attention Deficit Hyperactivity Disorder (ADHD) – Overview

Attention Deficit Hyperactivity Disorder ...

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Attention Deficit Hyperactivity Disorder (ADHD) – Overview

Attention Deficit Hyperactivity Disorder (ADHD) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Attention Deficit Hyperactivity Disorder (ADHD) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Attention Deficit Hyperactivity Disorder (ADHD) – Companies Involved in Therapeutics Development

4P-Pharma SAS

Aevi Genomic Medicine Inc

Amarantus Bioscience Holdings Inc

APeT Holding BV

Arcturus Therapeutics Ltd

BCWorld Pharm Co Ltd

BioHealthonomics Inc

Cingulate Therapeutics LLC

Collegium Pharmaceutical Inc

Curemark LLC

DURECT Corp

Heptares Therapeutics Ltd

Highland Therapeutics Inc

IRLAB Therapeutics AB

KemPharm Inc

leon-nanodrugs GmbH

Merck & Co Inc

Novartis AG

Noven Pharmaceuticals Inc

Otsuka Holdings Co Ltd

Otsuka Pharmaceutical Co Ltd

P2D Inc

RespireRx Pharmaceuticals Inc

Reviva Pharmaceuticals Inc

Shionogi & Co Ltd

Shire Plc

SK Biopharmaceuticals Co Ltd

Sunovion Pharmaceuticals Inc

Supernus Pharmaceuticals Inc

Taisho Pharmaceutical Holdings Co Ltd

Tris Pharma Inc

Attention Deficit Hyperactivity Disorder (ADHD) – Drug Profiles

4P-003 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

atomoxetine hydrochloride – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BCWPE-003 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

BNC-375 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CB-8411 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

centanafadine SR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CM-4612 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CX-717 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dasotraline – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dexmethylphenidate hydrochloride – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dextroamphetamine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dextroamphetamine IR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dextroamphetamine MR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Drugs for Attention Deficit Hyperactivity Disorder – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

eltoprazine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

fasoracetam – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

guanfacine – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

guanfacine hydrochloride ER – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

histamine dihydrochloride – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

HTL-1071 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INV-107 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KP-415 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

KP-484 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Leon-02 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

levofacetoperane – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

lisdexamfetamine dimesylate – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

mazindol CR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

methylphenidate ER – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

methylphenidate hydrochloride MR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

methylphenidate hydrochloride SR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

modafinil – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

molindone hydrochloride ER – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

niacinamide CR – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLS-2 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLS-4 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

NLS-8 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OPC-64005 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

P-001 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PBF-509 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PD-3044 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PFR-08001 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PFR-8026 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

RP-5063 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SERx–480 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

SKL-13865 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecule to Target Dopamine, Norepinephrine and Serotonin Transporter for Attention Deficit Hyperactivity Disorder – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Activate High Affinity Choline Transporter for Attention Deficit Hyperactivity Disorder – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit Dopamine, Serotonin, Norepinephrine Transporters for Central Nervous System Disorders – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Small Molecules to Inhibit SLC9A9 for ADHD – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TRN-110 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TS-141 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

viloxazine hydrochloride ER – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

VU-0238429 – Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects

Attention Deficit Hyperactivity Disorder (ADHD) – Discontinued Products

Attention Deficit Hyperactivity Disorder (ADHD) – Product Development Milestones

Featured News & Press Releases

Jul 19, 2018: Aevi Genomic Medicine Announces Novel Co-crystal Version of AEVI-001

Jul 12, 2018: Ironshore Pharmaceuticals Announces PDUFA Date of August 8, 2018 for HLD200

Jul 09, 2018: KemPharm Announces Top Line Results from KP415.E01 Efficacy and Safety Trial in Children With ADHD

Jun 12, 2018: 4P-Pharma, a recognized actor in the ADHD drug pipeline development

Jun 12, 2018: Aevi Genomic Medicine Provides Update on Sample Size Re-estimation for Phase 2 ASCEND Trial in ADHD

May 10, 2018: KemPharm Announces Positive, Topline Results from an Intravenous Human Abuse Potential Trial with KP415 Prodrug

May 02, 2018: Sunovion to Present Data on dasotraline at the 2018 American Psychiatric Association Annual Meeting

Mar 20, 2018: KemPharm Announces Positive Top line Results from KP415 Pharmacokinetic Study in Children and Adolescents With ADHD

Jan 15, 2018: Cingulate Therapeutics Presents New Data from its First in Human Proof of Concept Trial of CTX-1301 at the 2018 APSARD Annual Meeting

Jan 09, 2018: Cingulate Therapeutics to Present at 10th Annual Biotech Showcase

Jan 09, 2018: Cingulate Therapeutics to Present CTX-1302 at 10th Annual Biotech Showcase

Jan 08, 2018: KemPharm Initiates Pivotal Efficacy Trial of KP415

Jan 04, 2018: Cingulate Therapeutics to Present New Data from its First in Human Proof of Concept Trial of CTX-1301 at the 2018 APSARD Annual Meeting

Dec 18, 2017: RespireRx Pharmaceuticals Publishes Compelling Scientific Evidence Demonstrating the Neurobiological Safety of Ampakine CX717 and Justifying Continued Clinical Development

Nov 16, 2017: KemPharm Completes Successful End-of-Phase 2 Meeting on KP415 with FDA

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H2 2018

Number of Products under Development by Companies, H2 2018 ...

List of Tables

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Number of Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018 (Contd..1), H2 2018

Products under Development by Companies, H2 2018 (Contd..2), H2 2018

Products under Development by Universities/Institutes, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by 4P-Pharma SAS, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Aevi Genomic Medicine Inc, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Amarantus Bioscience Holdings Inc, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by APeT Holding BV, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Arcturus Therapeutics Ltd, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by BCWorld Pharm Co Ltd, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by BioHealthonomics Inc, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Cingulate Therapeutics LLC, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Collegium Pharmaceutical Inc, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Curemark LLC, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by DURECT Corp, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Heptares Therapeutics Ltd, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Highland Therapeutics Inc, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by IRLAB Therapeutics AB, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by KemPharm Inc, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by leon-nanodrugs GmbH, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Merck & Co Inc, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Novartis AG, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Noven Pharmaceuticals Inc, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Otsuka Holdings Co Ltd, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Otsuka Pharmaceutical Co Ltd, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by P2D Inc, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by RespireRx Pharmaceuticals Inc, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Reviva Pharmaceuticals Inc, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Shionogi & Co Ltd, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Shire Plc, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by SK Biopharmaceuticals Co Ltd, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Sunovion Pharmaceuticals Inc, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Supernus Pharmaceuticals Inc, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Taisho Pharmaceutical Holdings Co Ltd, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Pipeline by Tris Pharma Inc, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects, H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects, H2 2018 (Contd..1), H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects, H2 2018 (Contd..2), H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Dormant Projects, H2 2018 (Contd..3), H2 2018

Attention Deficit Hyperactivity Disorder (ADHD) – Discontinued Products, H2 2018

List of Figures

List of Figures

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H2 2018

Number of Products under Development by Companies, H2 2018 ...

List of Figures

Number of Products under Development for Attention Deficit Hyperactivity Disorder (ADHD), H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products under Development by Universities/Institutes, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2 2018

    Pricing

Discounts available for multiple report purchases.

reportstore@globalmarketsdirect.com
+44 (0) 161 359 5414

Saved reports